奥沙利铂与多西他赛分别联合氟尿嘧啶一线治疗晚期胃癌的疗效分析

Oxaliplatin combined with 5-fluorouracil and docetaxel respectively for first-line treatment of advanced gastric cancer curative effect analysis

目的回顾性分析以奥沙利铂为基础的FOLFOX-4方案与以多西他赛为基础的DF方案一线治疗晚期胃癌的临床疗效和毒副反应。方法收集我院55例晚期胃癌患者,一线应用FOLFOX-4方案26例,DF方案29例。所有患者至少接受3个周期FOLFOX-4方案或2个周期DF方案,且疗效可评价。结果 FOLFOX-4组客观有效率（ORR）为26.9%,疾病控制率（DCR）为73.1%,中位疾病无进展期（mPFS）为5.68个月,中位生存期（MST）为13.89个月。DF组ORR为20.7%,DCR为69%,mPFS为3.96月,MST为12.71个月。两组ORR、DCR、mPFS以及MST比较均差异无统计学意义（P〉0.05）。两组毒副反应出现Ⅲ～Ⅳ级白细胞减少DF组为多,两组比较有统计学意义（P〈0.05）。结论 FOLFOX-4和DF方案疗效相似,毒副作用可耐受,可以作为晚期胃癌的有效化疗方案选择。

Objective To compare the efficacy and safety of oxaliplatin combined with fluorouracil plus leucovorin（FOLFOX-4） and docetaxel combined with fluorouracil（DF） regimens as first line therapy for advanced gastric cancer（AGC）.Methods Fifty-five patients with AGC were treated with FOLFOX-4 or DF regimen as firtst line chemotherapy.All the patients received FOLFOX-4 at least 3 cycles or DF at least 2 cycles,efficacy can be evaluated as well.Results The overall response rate（ORR） was 26.9% and 20.7% to FOLFOX-4 and DF,disease control rate（DCR） of FOLFOX-4 was 73.1% and of DF was 69%,median survival times（MSTs） were 13.89 and 12.71 months respectively.No significant difference was observed in ORR,DCR or MST between the two groups.The incidence rate of grade 3/4 neutropenia in DF group was significantly higher than FOLFOX-4 group（P0.05）.Conclusion Both the DF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.